Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
Chamberlain
Marc C
MC
Lassman
Andrew B
AB
Iwamoto
Fabio M
FM
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011379:Prognosis
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab